Horizon Pharma Plc Stock Probability Of Bankruptcy
HZNPDelisted Stock | USD 100.40 0.13 0.13% |
Horizon |
Horizon Pharma PLC Company probability of distress Analysis
Horizon Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Horizon Pharma Probability Of Bankruptcy | Over 100% |
Most of Horizon Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Horizon Pharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Horizon Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Horizon Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Horizon Pharma PLC financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Horizon Pharma PLC has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Horizon Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Horizon Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Horizon Pharma could also be used in its relative valuation, which is a method of valuing Horizon Pharma by comparing valuation metrics of similar companies.Horizon Pharma is currently under evaluation in probability of bankruptcy category among its peers.
Horizon Fundamentals
Return On Equity | 0.0854 | |||
Return On Asset | 0.0444 | |||
Profit Margin | 0.12 % | |||
Operating Margin | 0.18 % | |||
Current Valuation | 26.87 B | |||
Shares Outstanding | 229 M | |||
Shares Owned By Insiders | 1.18 % | |||
Shares Owned By Institutions | 98.82 % | |||
Number Of Shares Shorted | 7.1 M | |||
Price To Earning | 32.55 X | |||
Price To Book | 5.10 X | |||
Price To Sales | 6.93 X | |||
Revenue | 3.63 B | |||
Gross Profit | 2.8 B | |||
EBITDA | 1.11 B | |||
Net Income | 521.48 M | |||
Cash And Equivalents | 2.13 B | |||
Cash Per Share | 9.40 X | |||
Total Debt | 2.56 B | |||
Debt To Equity | 0.53 % | |||
Current Ratio | 3.96 X | |||
Book Value Per Share | 23.20 X | |||
Cash Flow From Operations | 1.26 B | |||
Short Ratio | 2.04 X | |||
Earnings Per Share | 1.88 X | |||
Price To Earnings To Growth | 1.00 X | |||
Target Price | 116.5 | |||
Number Of Employees | 2.19 K | |||
Beta | 1.01 | |||
Market Capitalization | 26.63 B | |||
Total Asset | 9.11 B | |||
Retained Earnings | 590.01 M | |||
Working Capital | 2.7 B | |||
Current Asset | 1.11 B | |||
Current Liabilities | 357.55 M | |||
Z Score | 7.48 | |||
Net Asset | 9.11 B |
About Horizon Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Horizon Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Horizon Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Horizon Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Horizon Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Horizon Stock
Moving against Horizon Stock
0.88 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
0.75 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
0.71 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
0.68 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
0.67 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to Horizon Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Horizon Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Horizon Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Horizon Pharma PLC to buy it.
The correlation of Horizon Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Horizon Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Horizon Pharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Horizon Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |